The Argonaut clinical study is in collaboration with Persephone Biosciences and focuses on the identification of microbiome-based markers indicative of colorectal cancer, according to a Jan. 24 release.
The study will begin in the Toledo, Ohio, area with an initial cohort of 55 people with a range of colorectal cancer risks to further understand gut and immune health. Participants in the study will be enrolled at Kroger pharmacies and locations of the Little Clinic, a Kroger affiliate.
Kroger Health is seeking additional participants for the study who are 18 or older with one or more first-degree relatives with a history of colorectal cancer, 45 or older who need standard colon care, or who have had three or more polyps found during a colonoscopy or have a history of colon cancer.
This will be Kroger Health’s first clinical trial.
